Compare ARI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARI | VIR |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2009 | 2019 |
| Metric | ARI | VIR |
|---|---|---|
| Price | $11.16 | $10.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $11.00 | ★ $19.63 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 9.03% | N/A |
| EPS Growth | ★ 183.51 | 17.49 |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $271,589,000.00 | $68,556,000.00 |
| Revenue This Year | N/A | $270.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.09 | $4.16 |
| 52 Week High | $11.24 | $10.91 |
| Indicator | ARI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 64.90 | 66.51 |
| Support Level | $9.59 | $5.18 |
| Resistance Level | N/A | $10.91 |
| Average True Range (ATR) | 0.18 | 0.47 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 89.35 | 95.34 |
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.